Key Points
- Director Renee Tannenbaum sold 1,800 shares on Dec. 5 at an average price of $81.15 for $146,070, trimming her stake by 6.68% to 25,157 shares valued at about $2.04 million; the transaction was disclosed in an SEC filing.
- ANI recently beat quarterly estimates with EPS of $2.04 vs. $1.74 and revenue of $227.8M (up 53.6% YoY), issued FY2025 EPS guidance of 7.370–7.640, and carries a consensus "Buy" rating with an average price target of $99.38.
- Institutional interest is high: 76.05% of shares are held by institutions, with large recent stakes added by Arrowstreet, Balyasny, UBS and others.
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) Director Renee Tannenbaum sold 1,800 shares of the company's stock in a transaction dated Friday, December 5th. The shares were sold at an average price of $81.15, for a total transaction of $146,070.00. Following the transaction, the director owned 25,157 shares in the company, valued at approximately $2,041,490.55. The trade was a 6.68% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.
ANI Pharmaceuticals Stock Up 0.4%
Shares of NASDAQ:ANIP opened at $81.67 on Wednesday. ANI Pharmaceuticals, Inc. has a one year low of $52.50 and a one year high of $99.50. The company has a 50 day moving average of $88.09 and a 200-day moving average of $80.36. The company has a debt-to-equity ratio of 1.20, a current ratio of 2.58 and a quick ratio of 2.04. The stock has a market cap of $1.84 billion, a price-to-earnings ratio of 50.10 and a beta of 0.48.
ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last announced its quarterly earnings data on Friday, November 7th. The specialty pharmaceutical company reported $2.04 earnings per share for the quarter, beating the consensus estimate of $1.74 by $0.30. ANI Pharmaceuticals had a net margin of 4.91% and a return on equity of 26.73%. The business had revenue of $227.81 million for the quarter, compared to analyst estimates of $211.92 million. During the same period in the prior year, the business posted $1.34 earnings per share. ANI Pharmaceuticals's revenue was up 53.6% compared to the same quarter last year. ANI Pharmaceuticals has set its FY 2025 guidance at 7.370-7.640 EPS. On average, sell-side analysts forecast that ANI Pharmaceuticals, Inc. will post 3.86 earnings per share for the current year.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently added to or reduced their stakes in ANIP. Arrowstreet Capital Limited Partnership bought a new stake in shares of ANI Pharmaceuticals in the third quarter worth about $32,992,000. Balyasny Asset Management L.P. grew its position in shares of ANI Pharmaceuticals by 2,785.7% in the 3rd quarter. Balyasny Asset Management L.P. now owns 286,149 shares of the specialty pharmaceutical company's stock valued at $26,211,000 after purchasing an additional 276,233 shares during the period. Divisadero Street Capital Management LP bought a new stake in ANI Pharmaceuticals during the 3rd quarter worth approximately $21,454,000. Rubric Capital Management LP increased its stake in ANI Pharmaceuticals by 354.7% during the 2nd quarter. Rubric Capital Management LP now owns 257,669 shares of the specialty pharmaceutical company's stock worth $16,813,000 after purchasing an additional 200,998 shares in the last quarter. Finally, UBS Group AG raised its holdings in ANI Pharmaceuticals by 45.8% during the 3rd quarter. UBS Group AG now owns 589,874 shares of the specialty pharmaceutical company's stock worth $54,032,000 after buying an additional 185,172 shares during the period. 76.05% of the stock is owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
A number of research analysts have recently weighed in on ANIP shares. JPMorgan Chase & Co. increased their price target on ANI Pharmaceuticals from $95.00 to $115.00 and gave the company an "overweight" rating in a research note on Wednesday, September 24th. Truist Financial increased their target price on ANI Pharmaceuticals from $77.00 to $90.00 and gave the company a "hold" rating in a research note on Thursday, October 9th. Guggenheim raised their target price on ANI Pharmaceuticals from $114.00 to $115.00 and gave the stock a "buy" rating in a report on Monday, November 10th. HC Wainwright upped their price target on ANI Pharmaceuticals from $93.00 to $121.00 and gave the company a "buy" rating in a research note on Wednesday, September 17th. Finally, Barclays assumed coverage on shares of ANI Pharmaceuticals in a research report on Tuesday. They issued an "overweight" rating and a $100.00 price target on the stock. Two analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average price target of $99.38.
Get Our Latest Research Report on ANI Pharmaceuticals
ANI Pharmaceuticals Company Profile
(
Get Free Report)
ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
